Dosing and Switching Strategies for Paliperidone Palmitate
- 2.1k Downloads
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic recently approved by the US FDA and European Medicines Agency for use in patients with schizophrenia. This article reviews the recommended dosing regimens for initiation and maintenance treatment with paliperidone palmitate in adult patients with schizophrenia. We also address issues of switching to paliperidone palmitate from other antipsychotics, managing missed doses and dosing in special patient populations.
The dosing recommendations that were approved by the FDA and other regulatory agencies around the world are based on the results of population pharmacokinetic (PK) simulations and data from clinical trials that are presented in this review. A one-compartment disposition model with zero/ first-order absorption best described the PK of paliperidone palmitate. Population PK models for extended-release paliperidone and long-acting risperidone were also developed and we report the results from these models. The PK profiles for 5000 patients were simulated after paliperidone palmitate injections. The population median and 90% prediction intervals of the simulated plasma concentration versus time profiles after multiple doses are graphically displayed in this review. Based on the data from model-based PK simulations, the approved recommended initiation regimen for paliperidone palmitate is 150 mg equivalent (mg eq.) paliperidone (paliperidone palmitate 234 mg) on day 1 followed by 100 mg eq. paliperidone (paliperidone palmitate 156 mg) on day 8, each administered into the deltoid muscle, using a 1-inch 23-gauge needle in those weighing <90 kg and a 1.5-inch 22-gauge needle in those weighing ≥90 kg. No oral supplementation is required. Monthly maintenance dosing is in the range of 25–150 mg eq. paliperidone (paliperidone palmitate 39–234 mg; recommended dose of 75 mg eq. paliperidone [paliperidone palmitate 117 mg]) injected into the deltoid (needle size is weight adjusted) or gluteal (using a 1.5-inch 22-gauge needle) muscle. The day 8 dose may be administered ±2 days and monthly doses ±7 days, without a clinically significant impact on plasma concentrations. The re-initiation schedule in patients whose last maintenance dose was >6 weeks previously is dependent upon the duration of time since the last paliperidone palmitate injection.
In patients with mild renal impairment (creatinine clearance [CLCR]: 50–80 mL/min), dosage should be adjusted. No dose adjustment is required in patients with mild or moderate hepatic impairment; no data currently exist regarding severe hepatic impairment. Elderly patients with normal renal function should receive the same dosage as younger adult patients with normal renal function. In the event of an age-related decline in CLCR, dosage should be adjusted accordingly. Paliperidone palmitate can be initiated the day after discontinuing previous oral antipsychotic treatment. In patients switching from other LAIs (including long-acting risperidone), paliperidone palmitate dosing should be initiated at the time of what would have been the next scheduled injection of the previous LAI, and continued monthly thereafter.
In summary, following initiation dosing, paliperidone palmitate is administered on a monthly basis. It is the first of the second-generation anti-psychotics to be available and approved with this dosing regimen. Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic.
KeywordsRisperidone Paliperidone Paliperidone Palmitate Oral Antipsychotic Initiation Dose
The authors would like to thank Frances Gambling, Medicus International, for her editorial assistance (collating data, editing and proof reading) in the development of this manuscript. Editorial assistance was supported by funding from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
S.G., M.S., C.G.-M. and J.P. have disclosed that they are employees of Johnson & Johnson. S.G., M.S. and C.G.-M. have disclosed that they also own Johnson & Johnson stocks. L.A. has disclosed that he is an employee of Ortho-McNeil Janssen Scientific Affairs, LLC, a subsidiary of Johnson & Johnson.
- 1.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington (VA): American Psychiatric Publishing, Inc., 1994Google Scholar
- 4.Invega Sustenna™: US prescribing information [online]. Available from URL: http://www.invegasustenna.com/invegasustenna/shared/pi/invegasustenna.pdf [Accessed 2009 Sep]
- 9.Gopal S, Lindenmayer J, Hough D, et al. Safety and tolerability profiles of paliperidone palmitate injected into either the deltoid or gluteus muscle in patients with schizophrenia. 60th Annual Meeting of the Institute of Psychiatric Services; 2008 May 3–8; Chicago (IL)Google Scholar
- 10.Nasrallah H, Gopal S, Gassman-Mayer C, et al. Efficacy and safety of three doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia [poster no. 125]. 60th Annual Meeting of the Institute of Psychiatric Services; 2008 May 3–8; Chicago (IL)Google Scholar
- 13.Pandina G, Lindenmayer J, Lull J, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess efficacy and safety of paliperidone palmitate in adult subjects with schizophrenia [poster no. 31]. Annual Meeting of the International Congress of Schizophrenia Research; 2009 Mar 27–28; San Diego (CA)Google Scholar
- 14.Samtani M, Gopal S, Kern Sliwa J, et al. Paliperidone palmitate dosing in special populations: guidance based on pharmacokinetic modeling and simulation [poster no. K4]. American Conference on Pharmacometrics; 2009 Oct 4–7; Mashantucket (CT)Google Scholar
- 15.Samtani M, Gopal S, Kern Sliwa J, et al. Management of missed paliperidone palmitate doses based on pharmacokinetic modeling and simulation [poster no. II-62]. New Clinical Drug Evaluation Unit Annual Meeting; 2009 Jun 29–Jul 2; Hollywood (FL)Google Scholar
- 16.Samtani M, Gopal S, Kern Sliwa J, et al. Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulations [poster no. I-68]. New Clinical Drug Evaluation Unit Annual Meeting; 2009 Jun 29–Jul 2; Hollywood (FL)Google Scholar
- 17.Samtani M, Haskins J, Alphs L, et al. Maintenance dosing of once-monthly (4-weekly) paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on population simulations [poster no. 21]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–20; Jacksonville (FL)Google Scholar
- 18.Samtani M, Kern Sliwa J, Haskins J, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation [poster no. 19]. Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 2009 Apr 19–20; Jacksonville (FL)Google Scholar
- 20.Cirincione B, Redman M, Fiedler-Kelley J, et al. Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia [poster no. PI-21]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2007 Mar 21–24; Anaheim (CA)Google Scholar
- 21.Samtani M, Gopal S, Kern Sliwa J, et al. Switching to paliperidone palmitate from other depot antipsychotics: guidance based on pharmacokinetic simulations [abstract no. 1839]. Annual Meeting of the Population Approach Group in Europe; 2010 Jun 9–11; BerlinGoogle Scholar
- 26.Cleton A, Rossenu S, Crauwels H, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic, following administration in the deltoid or gluteal muscles [poster no. PI-74]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2008 Apr 2–5; Orlando (FL)Google Scholar
- 27.Cleton A, Rossenu S, Hough D, et al. Evaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia [poster no. PI-75]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2008 Apr 2–5; Orlando (FL)Google Scholar
- 28.Invega™: US prescribing information [online]. Available from URL: http://www.janssencns.com/invega-prescribing-information [Accessed 2011 Jul 21]
- 29.Fleischhacker W, Gopal S, Samtani M, et al. Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharmacokinetic simulations [poster no. 21]. Annual Meeting of American College of Neuropsychopharmcologists; 2008 Dec 7–11; Scottsdale (AZ)Google Scholar
- 30.Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 11: 12–25Google Scholar
- 33.Wikipidea, The Free Encyclopedia. Typical antipsychotic [online]. Available from URL: http://enwikipediaorg/wiki/Typical_antipsychotic [Accessed 2009 Aug 27]